Graphene Oxide/Silver Nanoparticle Coating Produced by Electrophoretic Deposition Improved the Mechanical and Tribological Properties of NiTi Alloy for Biomedical Applications

The aim of this study was to evaluate the mechanical and tribological properties of graphene oxide/silver nanoparticle (GO/AgNP) coated medical grade nickel-titanium (NiTi) alloy. The alloy substrates were coated using electrophoretic deposition at 30 V for 1, 5, and 10 min and were characterized by SEM, Raman spectroscopy, EDS, and surface profilometer. Mechanical and tribological tests were performed for hardness, Young's modulus, and friction coefficient. The data were analyzed using the Kruskal-Wallis test at a significance level of 0.05 to compare the coatings' roughness, thickness, friction coefficient, and hardness at the different coating times. The GO/AgNP coatings were confirmed with Raman spectroscopy, which demonstrated the presence of D bands and G bands at ∼1300 cm^-1 and ∼1600 cm^-1. The intensity ratios of the D and G bands (I_D/I_G) were 0.838, 0.836, and 0.837 in the 1, 5, and 10 min coated groups, respectively. The coating thickness ranged from 0.46-1.34 μm and the mean surface roughness (Ra) ranged from 50.72-69.93 nm. Increasing the coating time from 1-10 min increased the roughness, thickness, and Young's modulus of surface coating. The friction coefficients of the coated NiTi alloy were significantly lower compared with that of the uncoated NiTi allloy (p < 0.001). The GO/AgNP nanocomposite coated NiTi alloy demonstrated improved mechanical strength and a reduced friction coefficient that would be more favorable for biomedical applications.

Polymeric materials and films in dentistry: An overview

The use of polymeric materials (PMs) and polymeric films (PMFs) has increased in medicine and dentistry. This increasing interest is attributed to not only the excellent surfaces of PMs and PMFs but also their desired mechanical and biological properties, low production cost, and ease in processing, allowing them to be tailored for a wide range of applications. Specifically, PMs and PMFs are used in dentistry for their antimicrobial, drug delivery properties; in preventive, restorative and regenerative therapies; and for corrosion and friction reduction. PMFs such as acrylic acid copolymers are used as a dental adhesive; polylactic acids are used for dental pulp and dentin regeneration, and bioactive polymers are used as advanced drug delivery systems. The objective of this article was to review the literatures on the latest advancements in the use of PMs and PMFs in medicine and dentistry. Published literature (1990–2017) on PMs and PMFs for use in medicine and dentistry was reviewed using MEDLINE/PubMed and ScienceDirect resources. Furthermore, this review also explores the diversity of latest PMs and PMFs that have been utilized in dental applications, and analyzes the benefits and limitations of PMs and PMFs. Most of the PMs and PMFs have shown to improve the biomechanical properties of dental materials, but in future, more clinical studies are needed to create better treatment guidelines for patients.

Enhanced water-solubility and mucoadhesion of N,N,N-trimethyl-N-gluconate-N-homocysteine thiolactone chitosan

A water-soluble chitosan with improved mucoadhesion was prepared by modifying 19.4% of the amine groups of chitosan to trimethylammonium and conjugation of gluconolactone (GLU) and homocysteine thiolactone (HT) onto the remaining amine groups of the chitosan backbone. The derived trimethyl-gluconate-HT-chitosan (TM-GN-HT-chitosan) was confirmed by Fourier Transform Infrared spectroscopy, NMR and thermogravimetric analysis. The total thiol and disulfide group level on the TM-GN-HT-chitosan were 17.96 ± 0.03 and 7.36 ± 0.03 μmol/g, respectively. The water solubility of the TM-GN-HT-chitosan conjugate was 79.0 ± 0.15%, more than that of TM-chitosan and chitosan, with an enhanced solubility over a broad pH range ranging from 85.6 ± 10.4% to 58.5±1.1% maximal solubility at pH 2 to 11. Finally, TM-GN-HT-chitosan showed a nearly ∼9.5-, 5.0- and 5.6-fold higher mucoadhesiveness than chitosan at pH 1.2, 4.0 and 6.4, respectively, and was optimal at pH 4.0.

Electrospray fabrication of doxorubicin-chitosan-tripolyphosphate nanoparticles for delivery of doxorubicin

This work focused on a new technique for the preparation of doxorubicin (DOX) loaded chitosan (CS) nanoparticles (DOX-CS) - formation by electrospray ionization in the presence of tripolyphosphate (TPP) as the stabilizer. The working distance, needle gauge, flow rate, stirring rate, electrospraying voltage and DOX to CS molar ratio were sequentially and individually optimized and found to be a 26 gauge needle, an applied voltage of 13 kV, a flow rate of 0.5 mL/h, a working distance of 8 cm and a stirring rate of 400 rpm. The incorporation of chemically unchanged DOX with the CS into the particles was ascertained by Fourier transformed infrared spectroscopy (FT-IR), differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA). Under these optimized conditions, the DOX-CS particles were found to be nanoparticles of approximately 300-570 (dry particles) or 530-870 nm diameter (hydrated particles), with a PDI and SPAN polydispersity indices of 0.97-0.82 and 0.62-0.64, respectively, for initial DOX loading levels of 0.25-1%, as determined by SEM and particle size analyzer, respectively. Moreover, a high encapsulation efficiency (EE) of DOX into the nanoparticles was attained, ranging from 63.4 to 67.9% EE at 1 to 0.25% DOX loading. Finally, the in vitro DOX release behaviors of the DOX-CS particles revealed a prolonged release of DOX over at least seven hours.

Structure determination of diclofenac in a diclofenac-containing chitosan matrix using conventional X-ray powder diffraction data

The structure determination of diclofenac embedded in a diclofenac-containing chitosan matrix using conventional X-ray powder diffraction data is demonstrated. It reveals that sodium diclofenac, the starting material in the preparation of a controlled-release diclofenac-containing chitosan matrix, changes to diclofenac acid in space groupC2/cin the matrix. Simple methods were employed for handling the sample to obtain X-ray powder diffraction data of sufficiently high quality for the determination of the crystal structure of diclofenac embedded in chitosan. These involved grinding and sieving several times through a micro-mesh sieve to obtain a suitable particle size and a uniformly spherical particle shape. A traditional technique for structure solution from X-ray powder diffraction data was applied. The X-ray diffraction intensities were extracted using Le Bail's method. The structure was solved by direct methods from the extracted powder data and refined using the Rietveld method. For comparison, the single-crystal structure of the same drug was also determined. The result shows that the crystal structure solved from conventional X-ray powder diffraction data is in good agreement with that of the single crystal. The deviations of the differences in bond lengths and angles are of the order of 0.030 Å and 0.639°, respectively.